Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05878457 · ClinicalTrials.gov registry record · Phase 1

Accelerated rTMS for Post-Stroke Apathy

A Phase 1 study of Motivation and Stroke Sequelae, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT05878457 is a Phase 1 study of Motivation and Stroke Sequelae that has completed, run by Medical University of South Carolina. The registered enrollment target is 14 participants, below the 141-participant average among 13 other Motivation trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05878457, a Phase 1 study of Motivation and Stroke Sequelae, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

This pilot study will investigate the safety, feasibility, tolerability, and preliminary efficacy of accelerated high-dose repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC) to address apathy symptoms in individuals with chronic stroke.

Interventions

  • DEVICE MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System

Study Locations (1)

South Carolina

  • Medical University of South Carolina Brain Stimulation Lab - Charleston

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2023-12-01
Est. Completion 2025-04-30
Phase Phase 1

What the Registry Record Tells You About NCT05878457

The ClinicalTrials.gov registry entry for NCT05878457 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 13 other Motivation trials with a reported enrollment target (90% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Motivation appearing as the primary indexed condition, and to 1 intervention - of which MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System is the first listed.

NCT05878457 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT05878457 about?

NCT05878457 is a clinical study titled "Accelerated rTMS for Post-Stroke Apathy". This pilot study will investigate the safety, feasibility, tolerability, and preliminary efficacy of accelerated high-dose repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC) to address apathy symptoms in individuals with chronic stroke.

What is the current status of trial NCT05878457?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2023-12-01. Estimated completion is 2025-04-30.

What conditions does trial NCT05878457 study?

This clinical trial studies the following conditions: Motivation, Stroke Sequelae, Apathy, Stroke/Brain Attack, Abulia.

What interventions are being tested in trial NCT05878457?

The interventions under investigation include: MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (DEVICE).

Who is sponsoring clinical trial NCT05878457?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05878457 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Motivation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.